Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders

CALGARY, Dec. 15, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX: RVX) today announced that, at its annual and special meeting of shareholders held on December 15, 2016, Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated November 3, 2016 (the "Information Circular"), which is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.

1. Fixing the Number of Directors and Election of Directors

By resolution passed by ballot vote, each of the six nominees proposed as a director were elected as directors of the Corporation to hold office until the next annual meeting of Shareholders or until their successors are elected or appointed. 

The voting results for each nominee is set out below:

2. Appointment of Auditors

By resolution passed by show of hands, KPMG LLP, Chartered Accountants, was appointed as auditor of the Corporation to hold office until the next annual general meeting of the Shareholders and to authorize the Board to fix the auditor's remuneration.

3. Approval of Deferred Share Unit Plan

By resolution passed by ballot vote, the adoption of a Deferred Share Unit Plan of the Corporation (the "DSU Plan").

The results of the ballot were as follows:

4. Proposed Amendment to Royalty Preferred Shares

By resolution passed by ballot vote, a special resolution was passed to approve certain amendments to the terms of the Royalty Preferred Shares as outlined in the Information Circular. 

The results of the ballot were as follows:

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

For further information please visit www.resverlogix.com.

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog

For further information please contact:

Investor Relations
Email: [email protected]
Phone: 403-254-9252

SOURCE Resverlogix Corp.

Related Links

http://www.resverlogix.com